What Аугментин ЕС Treats: Main Uses and Benefits

This formulation is commonly used in the management of bacterial infections across several key domains. It is applied across domains where additional symptomatic support is needed for acute bacterial conditions, such as acute otitis media (middle ear infection), sinusitis, and certain lower respiratory tract infections, including community-acquired pneumonia.

This medicine is considered relevant in conditions characterized by recurrent or persistent manifestations. It is often applied in scenarios where symptoms become more noticeable, and is commonly applied in settings that involve acute or unstable symptom patterns. It assists with managing the infection, which helps address symptoms related to physical discomfort like noticeable ear pain or persistent facial pressure.

“It provides support that helps ease the overall symptom burden during difficult episodes.”

This approach contributes to the management of associated systemic imbalance, such as fever and general malaise, supporting the patient during episodes of heightened discomfort and assists with maintaining functional stability when symptoms interfere with routine activities.

---

Quick Fact: Relief for Acute Discomfort	Context	Benefit Provided
Conditions	Acute otitis media, sinusitis, lower respiratory tract infections, including pneumonia.
Symptom Focus	Heightened localized pain, persistent facial pressure, systemic fever, and malaise.
Clinical Scenario	Used in recurrent, persistent, or high-risk infections where symptoms are challenging.

---

The eligibility for using the specific formulation known as Augmentin ES-600 (Amoxicillin/Clavulanate) is strictly defined by regulatory documents, primarily confining its use to a specific pediatric population and excluding certain patient groups based on medical history.

Populations Who Must Not Use This Medicine (Contraindications)

Use of Augmentin ES-600 is formally prohibited for individuals with the following conditions:

• A history of a serious hypersensitivity reaction (e.g., anaphylaxis, Stevens-Johnson syndrome) to penicillins, cephalosporins, or any other beta-lactam antibiotics.
• A previous history of cholestatic jaundice or hepatic dysfunction (liver problems) associated with prior use of amoxicillin/clavulanate.

---

Eligibility and Restriction Rules

Eligibility Domain	Official Requirement/Restriction
Age and Weight	Indicated for pediatric patients (typically ge 3 months up to le 12 years old) weighing less than mathbf40 kg. Experience in patients outside this range is limited or not available.
Renal Function	Not recommended for patients with severe renal impairment (creatinine clearance <30 mL/min), as dosage adjustment recommendations are not available for this formulation.
Specific Conditions	Avoided in patients with suspected infectious mononucleosis due to a high risk of rash. Use with caution in patients with hepatic dysfunction and those with phenylketonuria (due to aspartame content).
Pregnancy/Lactation	Pregnancy: Use should be avoided unless considered essential by a physician. Lactation: May be administered while breastfeeding, with a noted risk of infant sensitization.

Interactions with other medicines and products

This section summarizes officially documented interactions for Augmentin ES (amoxicillin/clavulanate potassium) based on regulatory labeling and must not be used for clinical decision-making or as a substitute for professional medical advice.

Clinically Significant Interactions

Interacting Substance/Class	Official Interaction Statement
Probenecid	Concomitant use is not recommended. Probenecid decreases the renal tubular secretion of amoxicillin, resulting in increased and prolonged blood concentrations.
Oral Anticoagulants (e.g., Warfarin)	May lead to an increase in prothrombin time (INR). Monitoring of coagulation parameters is required upon co-administration or withdrawal.
Allopurinol	Increases the incidence of rash when co-administered.
Oral Contraceptives	May reduce the efficacy of oral contraceptives.

Food and Administration Requirements

To ensure optimal absorption, particularly of the clavulanate component, the medication is advised to be taken at the start of a meal.

Population-Based Restrictions

This extended-release formulation is not recommended for use in individuals with severe renal impairment (creatinine clearance < 30 mL/min) due to the risk of accumulation. This restriction is based on the drug's elimination profile and is tied to safe co-administration with the renal clearance process.

Аугментин ЕС is an antibacterial combination agent comprised of amoxicillin and clavulanate. Its primary action is the inhibition of bacterial cell wall synthesis by amoxicillin.

Amoxicillin covalently binds to and inactivates bacterial transpeptidases, which are known as Penicillin-Binding Proteins (PBPs). This binding prevents the essential cross-linking of peptidoglycan structures, leading to the disruption of cell wall integrity.

Clavulanate functions as a suicide beta-lactamase inhibitor. It binds to and inactivates a wide range of bacterial beta-lactamase enzymes. This specific interaction prevents the enzymatic hydrolysis of amoxicillin, ensuring that amoxicillin remains intact and available to exert its inhibitory effect on the bacterial cell wall synthesis pathway.

How to Use Аугментин ЕС: Official Administration Guidelines

Administration of the Аугментин ЕС (Augmentin ES-600) formulation is governed by specific instructions focusing strictly on high-dose pediatric use.

Principle	Official Labeled Instruction
Route and Form	Administered exclusively as an oral suspension. The powder requires reconstitution with water, and the suspension must be shaken well before each dose is measured.
Dosing Regimen	The dose is calculated based on the patient’s body weight, set at 90 mg/6.4 mg/kg/day (Amoxicillin/Clavulanate).
Frequency and Timing	The daily dose is divided into two equal portions and must be administered at 12 hourly intervals. The suspension should be taken at the start of a meal to minimize potential gastrointestinal intolerance.
Treatment Duration	The standard course of therapy is typically 10 days. Treatment should not be extended beyond 14 days without clinical reassessment.

---

Population-Specific Rules and Procedural Constraints

This high-ratio formulation is intended only for pediatric patients aged ge 3 months and < 40 kg. There is no established dosage for adults or children weighing ge 40 kg. Dose modification is not recommended for patients with severe renal impairment, defined as creatinine clearance less than 30 mL/min. The ES-600 suspension is not interchangeable with other Augmentin liquid formulations due to differences in clavulanic acid concentration, and consistent administration requires maintaining adequate fluid intake throughout the course of therapy.

Research Evidence: Overview of Studies for Аугментин ЕС

This section provides an overview of the clinical research and evidence types used by regulatory bodies to evaluate the high-dose Extra Strength (ES) formulation of co-amoxiclav, focusing on the study designs, populations, and measured outcomes. The findings described here reflect patterns observed in groups of people under specific study conditions and do not determine whether an individual will respond similarly.

---

Evidence for Use in Acute Otitis Media (AOM)

Research has primarily focused on children presenting with conditions characterized by fluctuating or episodic manifestations, such as recurrent AOM. Studies examined high-risk populations, including younger children (often under 2 years old), who had not responded to prior antibiotic treatments. The research explored how symptoms evolved in the observed populations, with studies monitoring outcomes related to physical discomfort and systemic or functional imbalance. Meta-analyses of the general amoxicillin-clavulanate combination described patterns observed in the measured clinical and bacteriological endpoints in studies of AOM in children. The targeted studies for the ES formulation monitored drug exposure in plasma and at the infection site to inform the selection of the high-dose regimen.

What is Still Uncertain in the Research Landscape

Follow-up durations were often limited to the short-term treatment course and a short period thereafter, meaning long-term effects are not fully established. The evidence provides limited information on the durability of the observed short-term responses. The certainty remains low regarding the comparative advantage of the ES-600 formulation versus other high-dose antibiotics, as comparative evidence is lacking or limited in publication. Many supporting studies were designed to investigate drug concentration levels (pharmacokinetics) rather than to examine comparative clinical endpoints against existing therapies.

Key Studies & References

1. A Pharmacokinetics and Safety Study of Augmentin Extra Strength (ES)-600 Suspension in Children Presenting With Community Acquired Pneumonia (CAP) and Acute Bacterial Rhinosinusitis (ABRS) in Brazil (NCT05340257)

Common questions about Аугментин ЕС (FAQ)

Q: Is Augmentin ES a standard antibiotic or something else?

Augmentin ES is officially categorized as a combination antibacterial drug, commonly known as an antibiotic. It belongs to the penicillin class and is paired with a beta-lactamase inhibitor, which is intended to extend its antibacterial activity.

Q: Why does the composition include two parts: amoxicillin and clavulanic acid?

The two-part composition is necessary because some bacteria can produce enzymes called beta-lactamases that destroy amoxicillin. Clavulanic acid acts as a protective shield, inhibiting these enzymes and allowing amoxicillin to remain intact and available to exert its intended effect.

Q: Can Augmentin ES cause stomach or intestinal problems?

Official product information confirms that common side effects include disturbances in the gastrointestinal tract. These typically involve issues such as nausea, vomiting, and diarrhea.

Q: Is there a risk of developing diarrhea when taking this medicine?

Yes, regulatory documents classify diarrhea as one of the most frequently reported adverse reactions associated with the use of Augmentin ES.

Q: How does Augmentin ES affect the liver?

Official safety information documents the potential for serious adverse reactions affecting the liver, including hepatic dysfunction and cholestatic jaundice. Official labeling indicates caution is required for the use of the medicine in patients who have pre-existing liver impairment.

Q: How does Augmentin ES affect the kidneys?

The kidneys are involved in eliminating amoxicillin from the body. Therefore, official regulatory constraints state that the medication is not recommended for patients with severe renal impairment (creatinine clearance less than 30 mL/min).

Q: Is Augmentin ES permitted while breastfeeding?

Both active substances are known to pass into breast milk. While use may be permitted, official guidance states that a physician must assess the potential benefit versus the risk of side effects to the infant, such as diarrhea or fungal infection (sensitization).

Q: Can I take Augmentin ES if I have mononucleosis?

Regulatory documents state that the use of Augmentin ES should be avoided in patients who have infectious mononucleosis. This restriction is based on the high risk of developing a skin rash in this patient population.

Q: Which laboratory tests might be required during treatment?

The medication may influence the results of certain laboratory tests. For instance, non-enzymatic methods for testing urine glucose may show false positive results, and the medication may also affect the results of the Coombs test. You should inform laboratory personnel that you are taking this medicine.

Q: How does Augmentin ES differ from regular Augmentin?

Augmentin ES-600 is distinguished by its unique high ratio of amoxicillin to clavulanic acid (14:1), designed for specific high-dose pediatric regimens. Official prescribing information explicitly states that this specific suspension is not interchangeable with other oral Augmentin formulations due to differences in composition.

Q: What should be done if a dose of the medication is missed?

If a dose is missed, regulatory patient information advises taking it as soon as possible. However, if it is almost time for the next scheduled dose, the missed dose is typically skipped to return to the regular dosing schedule. Official instructions state that a double dose should not be taken to compensate for a missed one.

Q: Can Augmentin ES affect blood test results?

Yes, the medication may influence the results of certain blood tests. Regulatory documents mention the potential for a false positive Coombs test and the need to monitor prothrombin time (a measure of blood clotting) for patients taking oral anticoagulants.

Q: Is Augmentin ES compatible with alcohol?

While official product labeling may not describe a direct interaction with alcohol, consuming alcohol during treatment can increase the risk of experiencing common side effects like nausea and vomiting, and regulatory guidelines suggest caution when consuming alcohol during treatment.

Q: Can Augmentin ES be given to children?

Yes, the Augmentin ES-600 formulation is specifically indicated in regulatory documents for the treatment of bacterial infections in pediatric patients, typically those aged 3 months and older and weighing less than 40 kg.

Q: Can Augmentin ES be used during pregnancy?

Official guidelines indicate that use of the medicine during pregnancy is generally avoided. It is stated that the medication should only be administered if the physician deems it essential after thoroughly assessing the potential benefits versus the risks.

Q: Why is this medication manufactured specifically as a suspension?

The medication is supplied as a powder for oral suspension because this liquid format facilitates accurate, weight-based dosing. This precise dosage calculation is required for the pediatric patient population for whom this formulation is primarily indicated.

Q: How does the Augmentin ES suspension differ from the tablets?

The Augmentin ES suspension is characterized by a unique high concentration ratio of active ingredients (14:1) that is not found in all other oral dosage forms. Official labeling cautions that this specific suspension is not interchangeable with other Augmentin formulations, including tablets.

Q: Can Augmentin ES cause drowsiness?

While official documents do not directly list drowsiness, possible side effects such as dizziness and headache are documented. These, along with other undesirable effects like convulsions, may indirectly influence a patient’s general well-being and alertness.

Q: What is the link between taking Augmentin ES and candidiasis (thrush)?

Official safety information lists mucocutaneous candidiasis (thrush) as a common side effect of this medicine. Antibiotics can sometimes disturb the body’s natural microbial balance, which can allow yeast overgrowth.

Q: Does the effectiveness of Augmentin ES depend on the patient's weight?

Yes, the precise calculation of the recommended dosage for Augmentin ES-600 is based directly on the patient’s body weight in kilograms. This calculation is a required part of the administration guidelines to ensure appropriate therapeutic levels are achieved.

Q: Why do doctors prescribe this specific composition (90:6.4)?

This specific high-ratio formulation is designed to provide the necessary concentration of amoxicillin to treat certain bacterial infections, such as specific cases of acute otitis media, which may be caused by bacteria with greater resistance. This ratio ensures appropriate therapeutic drug exposure at the site of infection.

Q: What should be done in case of an Augmentin ES overdose?

Signs of an overdose may include gastrointestinal disturbances and potential disturbances in fluid and electrolyte balance. In official guidance, any significant overdose necessitates immediate medical attention due to the documented risk of crystalluria (crystals in the urine) or renal failure.

Q: Does Augmentin ES affect the ability to drive a car?

Formal studies on the effects on the ability to drive or operate machinery have not been performed. However, due to the potential for side effects such as dizziness, headache, or convulsions, it is noted that the capacity to safely drive or use machines may be influenced.

Q: Can Augmentin ES be taken for infection prevention (prophylaxis)?

The medication is indicated for the treatment of infections caused by susceptible bacteria. Regulatory information also states that it may be used for the prevention of infections in specific clinical cases where the infection is strongly suspected or proven to be caused by susceptible bacteria.

Q: Is this medicine considered safe according to official regulators?

The Augmentin ES-600 formulation has successfully undergone the regulatory approval process and has been officially approved by authoritative bodies, such as the FDA, for use according to the indications described in the product labeling.

How to Store and Dispose of Augmentin ES-600

The storage of Augmentin ES-600 (amoxicillin/clavulanate potassium powder for oral suspension) is strictly governed by its form.

Storage Conditions

Product Form	Temperature Requirement	Additional Constraint
Dry Powder	Controlled room temperature (20°C to 25°C / 68°F to 77°F)	Protect from moisture; Store in original container
Reconstituted Suspension	Refrigerated (2°C to 8°C / 36°F to 46°F)	Do not freeze; Keep bottle tightly closed

Stability and Safety Rules

Once mixed, the reconstituted suspension must be discarded after 10 days of refrigeration, regardless of the amount remaining. All forms of the medicine must be stored out of the sight and reach of children.

Disposal Requirements

Expired or unused Augmentin ES-600 must be disposed of according to local regulations. This typically involves a medication take-back program; it must not be thrown into wastewater or general household trash.